

ANAGENICS

ASX ANNOUNCEMENT

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, Monday, 27 November 2023: Anagenics Limited (ASX:AN1) (the **Company**) is pleased to advise that shareholders of the Company passed all Resolutions by poll at the Annual General Meeting held today at 12:00pm (AEDT).

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act 2001*, a summary of the proxy votes and the total number of votes cast on each resolution in the poll is attached.

Approved for release by the Board of Directors of Anagenics Limited.

Investor Enquiries:

Scott Greasley
CEO
+61 412 308 263
info@anagenics.com

Anagenics Limited (ASX:AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

Disclosure of Proxy Votes

Anagenics Limited

Annual General Meeting 2023

Monday, 27 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	78,798,039	72,640,365 92.19%	6,097,674 7.74%	143,794	60,000 0.08%	73,454,514 92.34%	6,097,674 7.66%	125,308,942	Passed
2 Re-election of Mr Phillip Christopher as a Director	P	79,317,553	73,162,152 92.24%	6,095,401 7.68%	1,937,750	60,000 0.08%	199,141,449 97.03%	6,095,401 2.97%	1,937,750	Passed
3 Election of Ms Karen Matthews as a Director	P	79,317,553	73,221,652 92.31%	6,035,901 7.61%	1,937,750	60,000 0.08%	199,200,949 97.06%	6,035,901 2.94%	1,937,750	Passed
4 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	81,255,303	73,240,428 90.14%	7,954,875 9.79%	0	60,000 0.07%	199,219,725 96.16%	7,954,875 3.84%	0	Passed
5 Ratification of Prior Issue of Face Medi Group Shares	P	81,036,728	80,598,936 99.46%	377,792 0.47%	218,575	60,000 0.07%	206,578,233 99.82%	377,792 0.18%	218,575	Passed
6 Approval of issue of Options to Hancock & Gore Ltd, a substantial holder in the Company	P	33,088,011	26,853,015 81.16%	6,174,996 18.66%	37,750	60,000 0.18%	26,933,015 79.58%	6,909,145 20.42%	37,750	Passed
7 Approval of issue of Options to Phillip Christopher, a Director of the Company	P	32,981,967	24,937,146 75.61%	7,984,821 24.21%	143,794	60,000 0.18%	25,751,295 76.33%	7,984,821 23.67%	143,794	Passed
8 Appointment of Auditor	P	79,175,303	79,071,336 99.87%	43,967 0.06%	2,080,000	60,000 0.08%	205,050,633 99.98%	43,967 0.02%	2,080,000	Passed

